Amgen makes Repatha available through ‘AmgenNow’ direct to patient program

Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha. This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial. In support of the Trump Administration’s efforts to lower drug prices for Americans, Repatha will be available through AmgenNow at a monthly price of $239, nearly 60% lower than the current U.S. list price. The program is open to all patients, including those who are uninsured or in high-deductible health plans or prefer to pay with cash or out of pocket. The new direct-to-patient price is the lowest among the economically developed countries and is being offered exclusively for the first time to U.S. patients.